Compare OESX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OESX | SCLX |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 52.5M |
| IPO Year | 2007 | N/A |
| Metric | OESX | SCLX |
|---|---|---|
| Price | $10.25 | $9.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.50 | N/A |
| AVG Volume (30 Days) | 46.2K | ★ 119.0K |
| Earning Date | 02-05-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $86,306,000.00 | N/A |
| Revenue This Year | $7.94 | $122.52 |
| Revenue Next Year | $13.89 | $186.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.26 | N/A |
| 52 Week Low | $0.56 | $4.20 |
| 52 Week High | $18.64 | $34.27 |
| Indicator | OESX | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 62.25 |
| Support Level | $8.60 | $7.73 |
| Resistance Level | $10.38 | $12.32 |
| Average True Range (ATR) | 0.91 | 0.97 |
| MACD | -0.10 | 0.22 |
| Stochastic Oscillator | 31.73 | 74.96 |
Orion Energy Systems Inc provide light emitting diode (LED) lighting systems, wireless Internet of Things (IoT) enabled control solutions, commercial and industrial electric vehicle charging infrastructure solutions and lighting and electrical maintenance services. It help its customers achieve their sustainability, energy savings and carbon footprint reduction goals through technology and exceptional service. It sell its products and services into many vertical markets within the broader commercial and industrial market segment. Primary verticals include box retail, manufacturing, warehousing/logistics, federal and municipal government, healthcare and schools. It has three segments Lighting, Maintenance, and EV segment. It generates majority of revenue from Lighting segment.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.